InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report released on Sunday morning. The brokerage issued a sell rating on the stock.

InspireMD Stock Up 3.1 %

NYSE NSPR opened at $2.63 on Friday. The stock’s 50-day moving average price is $2.77 and its 200-day moving average price is $2.51. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.85. The company has a market capitalization of $65.57 million, a P/E ratio of -3.46 and a beta of 0.90.

InspireMD (NYSE:NSPR) last issued its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same period last year, the business posted ($0.24) EPS. Research analysts anticipate that InspireMD will post -0.82 EPS for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. purchased a new stake in shares of InspireMD, Inc. (NYSE:NSPR) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned approximately 0.13% of InspireMD at the end of the most recent reporting period. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.